Rigel Pharmaceuticals
RIGL
126 hedge funds and large institutions have $234M invested in Rigel Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 35 increasing their positions, 48 reducing their positions, and 17 closing their positions.
0.04% more ownership
Funds ownership: 8.83% → 8.87% (+0.04%)
6% less call options, than puts
Call options by funds: $48K | Put options by funds: $51K
7% less funds holding
Funds holding: 136 → 126 (-10)
26% less capital invested
Capital invested by funds: $316M → $234M (-$81.7M)
27% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 48
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
Top Buyers
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$3.08M |
| 2 |
Morgan Stanley
New York
|
+$2.99M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.83M |
| 4 |
Renaissance Technologies
New York
|
+$2.62M |
| 5 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$1.37M |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.34M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2M |
| 3 |
Goldman Sachs
New York
|
-$1.89M |
| 4 |
Two Sigma Investments
New York
|
-$1.71M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.69M |
RIGL Hedge Fund Activity: Q1 2020 in Review
126 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2020, worth a combined $234M — down 26% from $316M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RIGL and 8 opened new positions — a net loss of 9 holders — while 48 trimmed existing stakes and 35 added.
The largest buyer was Sofinnova Investments, opening a new position worth an estimated $3.08M. The largest seller was Wellington Management Group, cutting an estimated $2.34M.
- 126 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2020, down from 136 in Q4 2019.
- Funds reported $234M of Rigel Pharmaceuticals stock for Q1 2020, down 26% quarter-over-quarter.
- 8 funds opened new Rigel Pharmaceuticals positions in Q1 2020 and 17 closed out, a net change of -9 holders.
- The largest Rigel Pharmaceuticals buyer in Q1 2020 was Sofinnova Investments, an estimated $3.08M added.
- The largest Rigel Pharmaceuticals seller in Q1 2020 was Wellington Management Group, an estimated $2.34M sold.
Based on aggregated 13F filings for Q1 2020.